Evidence map›Paper›PMID 40153244›Full record

ArticleCardiovascular toxicology2025

Advanced Cardiovascular Toxicity Screening: Integrating Human iPSC-Derived Cardiomyocytes with 2D In Silico Models.

Anastasiya Sinitsyna, Andrey Berezhnoy, Ivan Semidetnov, Vadim Naumov, Tatyana Sergeeva, Sergey Bakumenko, Mikhail Slotvitsky, Valeriya Tsvelaya, Konstantin Agladze

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anastasiya SinitsynaLaboratory of Experimental and Cellular Medicine, Moscow Institute of Physics and Technology, Dolgoprudny, Russia, 141701.
Andrey BerezhnoyLaboratory of Experimental and Cellular Medicine, Moscow Institute of Physics and Technology, Dolgoprudny, Russia, 141701.
Ivan SemidetnovLaboratory of Experimental and Cellular Medicine, Moscow Institute of Physics and Technology, Dolgoprudny, Russia, 141701.
Vadim NaumovLaboratory of Experimental and Cellular Medicine, Moscow Institute of Physics and Technology, Dolgoprudny, Russia, 141701.
Tatyana SergeevaLaboratory of Experimental and Cellular Medicine, Moscow Institute of Physics and Technology, Dolgoprudny, Russia, 141701.
Sergey BakumenkoLaboratory of Experimental and Cellular Medicine, Moscow Institute of Physics and Technology, Dolgoprudny, Russia, 141701.
Mikhail SlotvitskyLaboratory of Experimental and Cellular Medicine, Moscow Institute of Physics and Technology, Dolgoprudny, Russia, 141701. slotvitsky.mm@gmail.com.
Valeriya TsvelayaLaboratory of Experimental and Cellular Medicine, Moscow Institute of Physics and Technology, Dolgoprudny, Russia, 141701. vts93@yandex.ru.
Konstantin AgladzeLaboratory of Experimental and Cellular Medicine, Moscow Institute of Physics and Technology, Dolgoprudny, Russia, 141701.

Funding

Ministry of Science and Higher Education of the Russian Federation #61Ministry of Science and Higher Education of the Russian Federation FSMG-2023-0015
6 · The paper itself

Abstract

The pharmaceutical industry is evolving with the use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) for in vitro cardiac safety screening. Traditional reliance on QT-interval prolongation as a main arrhythmogenicity marker is being challenged. In addition, the Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative recommends using computer modeling and in silico platforms as a more comprehensive approach for arrhythmogenicity testing in conjunction with hiPSC-CM in vitro screening. Our study presents an innovative platform that integrates in vitro hiPSC-CM propagation test with in silico models to assess the potential arrhythmogenic effect of drug-induced impact on ionic currents and electrophysiological intercellular coupling. Utilizing the electrophysiological and morphological characteristics of hiPSC-CM, we offer a thorough evaluation of potential drug-induced cardiac risks by computer modeling. We show, using the examples of lidocaine (100-300 μM) and Cyclophosphamide (639, 852 μM), that with the use of an integrative experimental and computer platform, it is possible to correctly display the clinical manifestations of side effects in advance.

Indexed as

Arrhythmias, CardiacDrug Evaluation, PreclinicalMyocytes, CardiacAnti-Arrhythmia AgentsCardiotoxicityCell LineComputer SimulationCyclophosphamideHumansInduced Pluripotent Stem CellsLidocaineAnti-Arrhythmia AgentsCyclophosphamideLidocaineArrhythmiaCardiac tissueComputer modelingExcitation waveInduced pluripotent stem cellsReentry

Identifiers

PMID40153244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.